IncobotulinumtoxinA (Xeomin): background, mechanism of action, and manufacturing.

Z. Paul Lorenc, Jeffrey M. Kenkel, Steven Fagien, Haideh Hirmand, Mark S. Nestor, Anthony P. Sclafani, Jonathan M Sykes, Heidi A. Waldorf

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


IncobotulinumtoxinA is the third botulinum neurotoxin type A (BoNTA) to be approved for aesthetic use in the United States. This article introduces the new product with an overview of clinical applications and a discussion of the neurotoxin's molecular structure. The role and clinical relevance of complexing proteins in BoNTA products are discussed. Finally, incobotulinumtoxinA's mechanism of action is described.

Original languageEnglish (US)
JournalAesthetic surgery journal / the American Society for Aesthetic Plastic surgery
Issue number1 Suppl
StatePublished - Mar 2013
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'IncobotulinumtoxinA (Xeomin): background, mechanism of action, and manufacturing.'. Together they form a unique fingerprint.

Cite this